^
Association details:
| Biomarker: | RET fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | EP0031 (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ellipses' Next Generation Selective RET Inhibitor EP0031/A400 Granted Fast Track Designation By US Food And Drug Administration
Published date:
03/05/2024
Excerpt:
...today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its next generation selective RET inhibitor EP0031/A400 for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC).
